Genes Analyzed in Genomind® Professional PGx ExpressTM

Genomind Professional PGx Express includes well-characterized, well-annotated genes, extensively supported in peer-reviewed publications to affect treatment for psychiatric conditions. It includes pharmacodynamic genes, which indicate the effect a drug has on the body and can inform drug candidate selection. It also includes pharmacokinetic genes, which indicate the effect the body has on the drug via metabolism and can inform drug dosage.

Genomind Professional PGx Express now includes two report options:

CORE Anxiety & Depression Report includes 15 key genes used to inform treatment decisions for anxiety and depression.

FULL Mental Health Report includes 24 key genes used to inform treatment for a range of psychiatric conditions such as depression, anxiety, attention deficit hyperactivity disorder (ADHD), bipolar, substance abuse and more.

United Healthcare now has a coverage policy for Genomind Professional PGx Express CORE Anxiety & Depression Report (15 genes).  The report includes 15 key genes used to inform treatment decisions for Anxiety and Depression. Coverage is for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication to treat their condition.

The Genomind Professional PGx Express test at a Glance

This table is for information purposes only. Full lab results include reference to published literature.

As the field of psychiatry moves more towards a biologically-based science, and as we learn more about the biological basis of psychiatric illnesses and their associated treatments, pharmacogenomics will continue to be an increasingly important additional tool for providers

Stephen M. Stahl, MD, PhDAdjunct Professor of Psychiatry University of California, San Diego (UCSD) - Genomind Scientific Advisory Board Member

} ); } ( jQuery ) );